Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep621 | Reproductive and Developmental Endocrinology | ECE2021

Experience of the transgender care unit

Moreno-Moreno Paloma , Ángel Rebollo-Román , Mª Rosa Alhambra Expósito , MaríaÁngeles Gálvez-Moreno

ObjectiveHealth care for transsexuals has changed in Andalucia since 2014. Our unit of attention to transsexual people began in 2015. The objective of this study is to analyze our experience.Patients and methodsRetrospective study by reviewing the medical records of the transsexuals treated in our unit.Results145 transsexual people. Transsexual man to woman (TMW):...

ea0070aep969 | Thyroid | ECE2020

Reducing unnecessary thyroid fine needle aspiration using ACR--TIRADS system

Alhambra Expósito Mª Rosa , Barrera-Martín Ana , Rebollo-Román Ángel , Segui-Azpilcueta Pedro , Ángeles Gálvez-Moreno María

Introduction: Thyroid ultrasound is the main technique to study this gland’s pathology. ACR TI-RADS system evaluates the malignancy risk in thyroid nodules according to their sonographic features and stablishes the size in which to perform fine needle aspiration (FNA) for its cytological study. Nodules diagnosed as Bethesda category 4 (B4) means are follicular neoplasms or suspicious for follicular neoplasms.Aim: Determine the pathology diagnosis o...

ea0070ep432 | Thyroid | ECE2020

Clinical approach after a Bethesda 4 result in a thyroid cytology

Alhambra Expósito Mª Rosa , Barrera-Martín Ana , Rebollo-Román Ángel , Segui-Azpilcueta Pedro , Ángeles Gálvez-Moreno María

Introduction: Thyroid nodules are a very common finding in sonographies (20–75% people). Criteria for clinical management and for cytological diagnosis (-Bethesda system) are well standardized. In spite of this, a gap of knowledge exists as far as management of Bethesda 4 is concerned.Aim: Evaluate the clinical approach of Bethesda 4 (B4) result in a thyroid cytology.Material and Methods: Retrospective study of thyroid nodule...

ea0073aep132 | Calcium and Bone | ECE2021

Bone mineral density evolution after Denosumab withdrawal

Mª Rosa Alhambra Expósito , Ana Barrera-Martín , Ángel Rebollo-Román , José Manuel Quesada Gómez , Maria Angeles Galvez Moreno

IntroductionDenosumab (Dab) withdrawal is associated with a quick loss in bone mineral density (BMD) and a high risk of multiple vertebral fractures. It is still not stablished which strategy best prevents BMD loss after Dab discontinuation.AimCompare the use of bisphosphonates for one year after Dab withdrawal versus a tapering Dab regimen in terms of BMD and fracture occurrence.Method...